Geode Capital Management’s Jasper Therapeutics JSPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$278K Buy
317,677
+105,820
+50% +$147K ﹤0.01% 3809
2025
Q4
$388K Buy
211,857
+81,002
+62% +$163K ﹤0.01% 3685
2025
Q3
$312K Sell
130,855
-275
-0.2% -$834 ﹤0.01% 3788
2025
Q2
$728K Sell
131,130
-132,554
-50% -$653K ﹤0.01% 3431
2025
Q1
$1.13M Buy
263,684
+5,997
+2% +$39.9K ﹤0.01% 3261
2024
Q4
$5.51M Buy
257,687
+271
+0.1% +$5.64K ﹤0.01% 2697
2024
Q3
$4.84M Sell
257,416
-2,338
-0.9% -$46.6K ﹤0.01% 2774
2024
Q2
$5.9M Buy
259,754
+131,763
+103% +$3.16M ﹤0.01% 2634
2024
Q1
$3.76M Buy
127,991
+37,543
+42% +$667K ﹤0.01% 2855
2023
Q4
$714K Hold
90,448
﹤0.01% 3475
2023
Q3
$633K Sell
90,448
-6,102
-6% -$74.5K ﹤0.01% 3511
2023
Q2
$1.32M Sell
96,550
-10,481
-10% -$156K ﹤0.01% 3249
2023
Q1
$1.94M Buy
107,031
+94,289
+740% +$1.74M ﹤0.01% 3044
2022
Q4
$60K Sell
12,742
-31
-0.2% -$208 ﹤0.01% 4542
2022
Q3
$100K Hold
12,773
﹤0.01% 4578
2022
Q2
$246K Hold
12,773
﹤0.01% 4139
2022
Q1
$453K Buy
12,773
+1,068
+9% +$48.1K ﹤0.01% 3980
2021
Q4
$918K Buy
+11,705
New +$1.1M ﹤0.01% 3763
2021
Q1
Sell
-2,563
Closed -$258K 4458
2020
Q4
$258K Sell
2,563
-787
-23% -$78.3K ﹤0.01% 3805
2020
Q3
$331K Hold
3,350
﹤0.01% 3567
2020
Q2
$335K Hold
3,350
﹤0.01% 3503
2020
Q1
$319K Buy
+3,350
New +$328K ﹤0.01% 3409

Other funds holding JSPR

Geode Capital Management's JSPR Position: Q1 2026 in Review

Geode Capital Management increased its Jasper Therapeutics (JSPR) stake by 50% in Q1 2026, buying an estimated $147K and bringing the position to 317,677 shares worth $278K. The position accounts for ﹤0.01% of the portfolio, ranked #3809.

Geode Capital Management first reported a position in JSPR in Q1 2020 and has held it in 22 quarters since. The position peaked at $5.9M in Q2 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Geode Capital Management held 317,677 shares of Jasper Therapeutics worth $278K as of Q1 2026.
  • Geode Capital Management bought 105,820 Jasper Therapeutics shares in Q1 2026, an estimated $147K.
  • Jasper Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3809 holding.
  • Geode Capital Management first reported a position in Jasper Therapeutics in Q1 2020 and has held it in 22 quarters since.
  • Geode Capital Management's Jasper Therapeutics position peaked at $5.9M in Q2 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.